NewAmsterdam Pharma Company N.V. Payments to Acquire Productive Assets
NewAmsterdam Pharma Company N.V. (NAMS) reported Payments to Acquire Productive Assets of $118.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. payments to acquire productive assets for the quarter ending 2026-06-30 was $80.00K, a 9.09% decline year-over-year.
- NewAmsterdam Pharma Company N.V. payments to acquire productive assets for the quarter ending 2026-03-31 was $38.00K, a 137.50% increase year-over-year.
- NewAmsterdam Pharma Company N.V. payments to acquire productive assets for the quarter ending 2025-12-31 was $100.00K, a 3233.33% increase year-over-year.
- NewAmsterdam Pharma Company N.V. payments to acquire productive assets for the quarter ending 2025-09-30 was $42.00K, a 44.00% decline year-over-year.
- NewAmsterdam Pharma Company N.V. payments to acquire productive assets for fiscal 2025 was $246.00K, a 63.39% decline from fiscal 2024.
- NewAmsterdam Pharma Company N.V. payments to acquire productive assets for fiscal 2024 was $672.00K, a 2700.00% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. payments to acquire productive assets for fiscal 2023 was $24.00K, a 89.14% decline from fiscal 2022.
- NewAmsterdam Pharma Company N.V. payments to acquire productive assets for fiscal 2022 was $221.00K, a 820.83% increase from fiscal 2021.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $118.00K 10-Q · filed 2026-08-05 | $218.00K derived: sum of 3 quarters · filed 2026-08-05 | $260.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $38.00K 10-Q · filed 2026-05-07 | $138.00K derived: sum of 2 quarters · filed 2026-05-07 | $180.00K derived: sum of 3 quarters · filed 2026-05-07 | $268.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $142.00K derived: sum of 2 quarters · filed 2026-02-18 | $230.00K derived: sum of 3 quarters · filed 2026-08-05 | $246.00K 10-K · filed 2026-02-18 |
| 2025-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $130.00K derived: sum of 2 quarters · filed 2026-08-05 | $146.00K 10-Q · filed 2025-11-05 | $149.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $104.00K 10-Q · filed 2026-08-05 | $107.00K derived: sum of 3 quarters · filed 2026-08-05 | $182.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $16.00K 10-Q · filed 2026-05-07 | $19.00K derived: sum of 2 quarters · filed 2026-05-07 | $94.00K derived: sum of 3 quarters · filed 2026-05-07 | $303.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $78.00K derived: sum of 2 quarters · filed 2026-02-18 | $287.00K derived: sum of 3 quarters · filed 2026-02-18 | $672.00K 10-K · filed 2026-02-18 |
| 2024-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $284.00K derived: sum of 2 quarters · filed 2025-11-05 | $669.00K 10-Q · filed 2025-11-05 | $672.00K derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | $209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $594.00K 10-Q · filed 2025-08-06 | $597.00K derived: sum of 3 quarters · filed 2026-02-18 | $606.00K derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | $385.00K 10-Q · filed 2025-05-08 | $388.00K derived: sum of 2 quarters · filed 2026-02-18 | $397.00K derived: sum of 3 quarters · filed 2026-02-18 | $402.00K derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $12.00K derived: sum of 2 quarters · filed 2026-02-18 | $17.00K derived: sum of 3 quarters · filed 2026-02-18 | $24.00K 10-K · filed 2026-02-18 |
| 2023-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $14.00K derived: sum of 2 quarters · filed 2024-11-06 | $21.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $12.00K 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $7.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $221.00K 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $24.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |